Insurance Gaps in Ketamine Care — And One Fix

The Coverage Wall Most Patients Hit

A Daily Northwestern report published April 15, 2026 highlights what many ketamine patients already know firsthand: the treatment is clinically effective, increasingly available, and almost entirely out-of-pocket for most Americans. The piece profiles a Chicago-area foundation stepping in to subsidize treatment costs for patients who cannot afford to wait — or pay — for insurance to catch up.

The underlying tension is straightforward. Ketamine, particularly IV ketamine and the FDA-approved esketamine nasal spray (Spravato), has accumulated a meaningful evidence base for treatment-resistant depression over the past decade. Yet most commercial insurers continue to classify infusion-based ketamine as experimental, leaving patients to absorb costs that routinely run $400–$800 per infusion session — and most induction courses require six sessions. For low-dose oral and sublingual ketamine protocols, which sit outside the FDA-approved indications entirely, coverage is effectively nonexistent.

Why Insurers Are Still Holding Back in 2026

The insurance industry's resistance isn't purely arbitrary, though it is frustrating. Coverage decisions hinge on a specific evidentiary standard: large, randomized controlled trials with long-term follow-up data, ideally published in peer-reviewed journals and endorsed by major clinical bodies. Ketamine's evidence base, while genuinely promising, has gaps that insurers continue to exploit as justification for denial.

Most ketamine depression studies have been relatively small, short in duration, and conducted in highly controlled clinical settings that don't always reflect real-world administration. The durability question — how long do antidepressant effects last, and what does a sustainable maintenance protocol look like — remains one of the field's active research frontiers. Insurers point to these gaps. Clinicians and patients point to the human cost of waiting.

There's also a classification problem. IV ketamine is administered off-label for depression; it has no FDA approval for that indication. Spravato does, but its coverage pathway involves prior authorization hurdles, step therapy requirements, and restricted in-office administration rules that create their own access barriers. Oral and sublingual low-dose ketamine, increasingly used in outpatient psychiatric and primary care settings, doesn't fit neatly into any reimbursement category at all.

What Foundation-Based Models Actually Solve — and Don't

The Chicago foundation highlighted in the Northwestern piece represents a category of stopgap solutions that has grown alongside ketamine's clinical footprint. Patient assistance programs, nonprofit subsidies, sliding-scale clinic fees, and HSA/FSA utilization strategies have collectively made treatment accessible to patients who would otherwise be priced out. These models matter. They are also, by definition, limited in scale and not a substitute for systemic coverage reform.

For readers navigating low-dose ketamine specifically, the financial picture is somewhat more variable than for IV infusion. Sublingual and oral protocols administered through telehealth-adjacent psychiatric services have lower per-session costs, and some providers have structured maintenance programs that reduce the ongoing expense relative to infusion series. That said, "more affordable" is not the same as "covered," and out-of-pocket costs remain a real barrier for patients on fixed incomes, without savings, or managing comorbid conditions that compound treatment costs.

The broader implication of stories like this one is that the gap between clinical evidence and coverage policy is a structural problem — not a temporary lag that will resolve itself in the next year or two. Legislative and regulatory pressure, including ongoing state-level parity advocacy and federal bills that would require coverage parity for mental health treatments with demonstrated efficacy, is the more durable lever. That work is slow.

What This Means If You're Currently in Treatment or Considering It

For patients already in a low-dose ketamine program, the insurance landscape in 2026 means a few practical things. First, document everything: diagnosis codes, provider notes, treatment rationale, and any prior treatment failures. If you ever pursue an insurance appeal — and it is worth doing — that documentation is your foundation. Second, ask your provider explicitly whether they have experience with insurance appeals or reimbursement navigation. Some practices have staff dedicated to this; others don't engage with it at all.

Third, understand what you're paying for at each stage of treatment. Induction, maintenance, and any associated psychiatric oversight or therapy are often billed separately. Knowing the cost structure of your specific protocol helps you anticipate expenses and identify where assistance programs might apply. Several national and regional nonprofits now offer grants or sliding-scale support specifically for ketamine-based mental health treatment — your provider or clinic should be able to connect you with relevant resources.

Finally, keep watching the coverage landscape. The evidentiary case for ketamine in depression is not standing still. Larger trials, longer follow-up data, and growing clinical consensus are the inputs that eventually move insurer policy — even if the timeline is measured in years, not months.